Signs of viral infection include fatigue, loss of appetite, weight loss, fevers, night sweats, chills, aches, viral conjunctivitis or "pink eye," itchy, burning sensation, jaundice, and pains. [7] An individual could be HBsAg seronegative due to clearance of the antigen from the body or when such an individual is not infected. Malaise is a nonspecific sign/symptom which includes general discomfort and pain which used to be the first indication of an infection or disease. There is little information on the frequency of HBeAg, HBeAb, anti-HIV, and anti-HCV in HBsAg-seronegative anicteric malaise patients. This work determined the pattern of HBeAg, HBeAb, anti-HIV, and anti-HCV in HBsAg-seronegative anicteric malaise patients.
methods

Study area
Ado Ekiti is the state capital of Ekiti state in South Western zone of Nigeria. It hosts Ekiti State University Ado-Ekiti, Afe Babalola University, Federal Polytechnic, Ado-Ekiti, Crown polytechnic, Nigerian Television Authority, Ekiti State Television, Radio Ekiti, and Progress FM and Voice FM radio stations. The city is a major trade center for yams, cassava, grain, cotton, and tobacco.
Study population
The study population included 200 malaise anicteric HBsAg-seronegative patients (females -100 and males -100) aged 5-76 years attending Clinical Outpatient of Ekiti State Teaching Hospital, Ado-Ekiti, Nigeria, and 111 apparently healthy nonmalaise age-matched subjects who were HBsAg seronegative (females -56 and males -55) were recruited as test and control subjects, respectively.
Immunochemical assays
Determination of hepatitis B viral biomarkers: a. Patients were pre-and posttest counseled for the tests b. HBsAg test was carried out in all the volunteers using the reagent kit of BIO-RAD Raymond Poincare, Marnes-la Coquette.
Principle
This is a sandwich enzyme-linked immunosorbent assay that uses three monoclonal antibodies that could bind to their corresponding subtypes of HBsAg. The solid phase is polystyrene microwells coated with the first monoclonal antibody, while the other two monoclonal antibodies are bound to the enzyme peroxidase. They bind their corresponding HBsAg to generate an observable reaction in form of color formation.
The assay procedure includes the following reaction steps: 1. Distribution of samples into the wells of the microplates: This distribution can be visually controlled; there is a clear difference of coloration between the empty well and well with the sample. This distribution can also be controlled automatically by reading at 450/620-700 nm (optional) 2. Distribution of the conjugate into the wells: This distribution can also be visually controlled; the conjugate which is initially orange becomes red after addition into the well. It is possible to control automatically this distribution by spectrophotometric reading at 450/620-700 nm (optional). The sample deposition can also be controlled at this step of the manipulation by automatic reading at 450/620-700 nm 3. Incubation at 37°C 4. Washing and development of the enzyme activity-bound solid phase by the addition of substrate 5. Stopping development, then reading of the optical densities at 450/620-700 nm and interpretation of the results 6. HBeAg and anti-HBe tests were determined in the plasma of the subjects using the reagent kit of DIA. PRO, Diagnostic Bioprobes Srl Via Columella, Milano, Italy.
Principle of the test
i. HBeAg: Hepatitis B envelope antigen (HBeAg) in the plasma binds with its corresponding anti-HBeAg antibodies after incubation and washing this complex in turn binds the peroxidase enzyme added to the microplate. The reaction is made observable by the addition of chromogen substrate ii. Anti-HBeAg: anti-Hbe in the plasma or serum competes with recombinant HBeAg for the binding site on anti-HBeAg antibody on the microplate wells. Two anti-HBeAg monoclonal antibodies bind to peroxidase and chromogen-substrate complex is added for the formation of color.
HIV tests
HIV screening was carried out on the participants using Abbott Determine HIV-1/2, a reagent kit of Abbot Laboratories Co., Ltd., Japan.
HIV confirmatory test
The HIV confirmatory test was carried out on all the participants by Western blot assay, using reagent kit of Immunoetics, Inc., 27 Dryclock Avenue, Boston, USA. http//www.immunoetics. com
Anti-HCV test
Anti-HCV test was determined on all the participants using the reagent kit of DIA.PRO, Diagnostic Bioprobes Srl Via Columella, Milano, Italy.
Principles of the test microplates are attached with HCV-specific antigens which bind with the antibody from the plasma or serum. The reaction is made observable by the addition of antiglobulin and IgM antibody, labeled with peroxidase. 
Ethical consideration
Data analysis
The results obtained were subjected to statistical analysis to evaluate the mean, frequency, and percentage using the Statistical Package for the Social Sciences version 18.0.
results
The results obtained showed a frequency of occurrence of 3% (6) HBeAg; 9.5% (19) HBeAb; 3.5% (7) anti-HIV; 6.5% (13) anti-HCV; 1% (2) anti-HIV + HBeAg; 0.5% (1) anti-HIV + HBeAb; 0.5% (1) anti-HIV + anti-HCV; and 0.5% (1) Anti-HIV + Anti-HCV + HBeAg [ Table 1 and Figure 1 ].
About 9.5% (19) HBeAb was most frequent, followed by 6.5% (13) anti-HCV; 3.5% (7) anti-HIV and 3% (6) HBeAg were more in females than males. There was a low frequency of coexpression of viral biomarkers: 1% (2) anti-HIV + HBeAg; 0.5% (1) anti-HIV + HBeAb; 0.5% (1) anti-HIV + anti-HCV; a n d 0 . 5 % ( 1 ) a n t i -H I V + a n t i -H C V + H B e A g [ Table 1 and Figure 1 ].
About 25% (50/200) malaise HBsAg-seronegative patients expressed at least one of the HIV, HCV, and HBV serologic markers compared with 9.9% (11/111) in the control subjects [ Table 1 ].
dIscussIon
This study was used to determine the pattern of HBe antigen, HBe antibody, HIV antibody, and HCV antibody in HBsAg-seronegative anicteric malaise patients. The results obtained showed a frequency of immunochemical viral biomarkers as follows: 3% (6) HBeAg; 9.5% (19) HBeAb; 3.5% (7) anti-HIV; 6.5% (13) anti-HCV; 1% (2) anti-HIV + HBeAg; 0.5% (1) anti-HIV + HBeAb; 0.5% (1) anti-HIV + anti-HCV; and 0.5% (1) anti-HIV + anti-HCV + HBeAg. Approximately 9.5% (19) HBeAb was most frequent, followed by 6.5% (13) anti-HCV; 3.5% (7) anti-HIV and 3% (6) HBeAg were more in females than the males. HBeAb indicates clearance of the envelope antigen to hepatitis B virus and convalescence though the patient is hepatitis B virus infected. HBeAg indicates active hepatitis B virus infection and replication. The presence of antibodies to HIV and HCV is an indication of HIV and HCV infection, respectively. Antibody to HBe which is most prevalent in this work could be attributed to high prevalence of Hepatitis B virus relative to the prevalence of HIV and HCV in Nigeria [8] which Otegbayo et al. [9] reported as 11.9%, HBsAg and 4.8%, anti-HCV. Otegbayo et al. [9] also reported gender difference in HCV and HBV serologic markers. HBsAg was more common among males than females, while anti-HCV was found in a similar proportion in males and females.
There was a low frequency of coexpression of viral biomarkers: 1% (2) nti-HIV + HBeAg; 0.5% (1) anti-HIV + HBeAb; 0.5% (1) nti-HIV + nti-HCV; and 0.5% (1) nti-HIV + nti-HCV + HBeAg. This finding agrees with the report of Muriuki et al. [10] on the prevalence of hepatitis B and C viral coinfections among HIV-1-infected individuals in Nairobi, Kenya. Muriuki et al. [10] reported low levels of coinfection with all three viruses, but there could be higher prevalence rates specifically in high-risk populations. The low frequency of viral coinfections found in this study could also be higher but possibly due to high-death rate associated with viral coinfections as HIV-positive individuals coinfected with HBV and/or HCV have increased rates of progression to chronic hepatitis infection, fibrosis, cirrhosis, hepatocellular carcinoma, and end-stage liver disease. [1, [11] [12] [13] [14] About 25% (50/200) malaise HBsAg-seronegative patients expressed at least one of the HIV, HCV, and HBV serologic markers compared with 9.9% (11/111) in the control subjects. This finding could be explained as malaise involves general discomfort, uneasiness, or pain, which is the first thought as an indication of infection or other diseases as signs and symptoms of viral infection of the viruses in this work include fatigue, nausea, muscle or joint pains, general ill-health, loss of appetite, nausea, vomiting, body aches, and mild fever. [3, 6, 15] conclusIon
The work also showed a frequency of occurrence of 3% (6) HBeAg; 9.5% (19) HBeAb; 3.5% (7) anti-HIV; 6.5% (13) anti-HCV; 1% (2) anti-HIV + HBeAg; 0.5% (1) anti-HIV + HBeAb; 0.5% (1) anti-HIV + anti-HCV; and 0.5% (1) anti-HIV + anti-HCV + HBeAg, with 9.5% (19) HBeAb found to be most frequent followed by 6.5% (13) anti-HCV; 3.5% (7) anti-HIV and 3% (6) HBeAg were more in females than the males. About 25% (50/200) malaise HBsAg-seronegative patients expressed at least one of the HIV, HCV, and HBV serologic markers compared with 9.9% (11/111) in the control subjects. There was a low frequency of coexpression of viral biomarkers (0.5%-1%).
Routine evaluation of HBeAg, HBeAb, anti-HIV, and anti-HCV in HBsAg-seronegative anicteric malaise patients will provide useful direction for effective management of malaise patients.
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